GLOW is not a single peptide. It is a commercially assembled research blend of three separately characterised compounds co-lyophilized in one vial, most commonly 70 mg total: GHK-Cu 50 mg, BPC-157 10 mg, and TB-500 10 mg. The name is a market convention; no regulatory body, pharmacopoeia, or chemical database recognises “GLOW” as a compound. Because the vial holds three distinct molecules, it has no single amino-acid sequence and no single molecular weight, and any source publishing one has invented it.
The components come from different places in the literature. GHK-Cu is a copper-chelating tripeptide isolated from human plasma albumin in 1973, with a long record in topical wound-healing and cosmetic research. BPC-157 is a synthetic 15-residue peptide corresponding to a partial sequence of a protein found in human gastric juice, studied almost entirely in rodent injury models. TB-500 denotes material derived from thymosin beta-4, the principal actin-sequestering protein in mammalian cells, and is named after its actin-binding LKKTETQ motif at residues 17-23 of the mature chain.
A labelling ambiguity worth noting
“TB-500” is unreliable as an identifier. Some material sold under that name is the acetylated heptapeptide Ac-LKKTETQ (889.0 g/mol); other material is full-length thymosin beta-4 at roughly 4,963 g/mol. These are chemically distinct molecules with different evidence bases, and the substantial human clinical work was done on the full-length protein rather than the fragment. Naming is muddled on the GHK side too: databases carry “GHK-Cu” and “prezatide” as synonyms of the copper-free tripeptide, and list 2:1 complexes alongside the predominant 1:1 form. The certificate of analysis, not the product name, is the only reliable statement of what a vial contains.
The central point about GLOW as a formulation is that the combination is untested. No peer-reviewed study has examined all three compounds together, or even any two of them. The 50/10/10 ratio has no published basis and is not standardized – some suppliers sell 30 mg vials at other ratios. Co-formulation raises unstudied questions of its own: the stability of a copper complex lyophilized alongside two peptides, a pharmacokinetic mismatch between components cleared on very different timescales, and the copper load from the dominant GHK-Cu fraction – roughly 7.9 mg of elemental copper per 50 mg, by a route that bypasses gastrointestinal copper regulation.
None of the three components is approved for human therapeutic use. The individual compounds range from moderately to sparsely characterised, and the blend itself is uncharacterised.